Lifeboat Foundation

Glioblastoma Multiforme (GBM) is the most aggressive and most common primary malignant brain tumor. The age of GBM patients is considered as one of the disease’s negative prognostic factors and the mean age of diagnosis is 62 years. A promising approach to preventing both GBM and aging is to identify new potential therapeutic targets that are associated with both conditions as concurrent drivers. In this work, we present a multi-angled approach of identifying targets, which takes into account not only the disease-related genes but also the ones important in aging. For this purpose, we developed three strategies of target identification using the results of correlation analysis augmented with survival data, differences in expression levels and previously published information of aging-related genes.

A team of engineers at the University of Colorado Boulder has designed a new class of tiny, self-propelled robots that can zip through liquid at incredible speeds—and may one day even deliver prescription drugs to hard-to-reach places inside the human body.

The researchers describe their mini healthcare providers in a paper published last month in the journal Small.

“Imagine if microrobots could perform certain tasks in the body, such as non-invasive surgeries,” said Jin Lee, lead author of the study and a postdoctoral researcher in the Department of Chemical and Biological Engineering. “Instead of cutting into the patient, we can simply introduce the robots to the body through a pill or an injection, and they would perform the procedure themselves.”

Israeli-based health tech company Cordio has developed machine learning software that can be downloaded to a smartphone and help keeps cardiac patients out of the hospital.

One day in the future.

It’s a simple daily habit that could save their life, because one day after repeating their daily refrain, their doctor might be notified that a patient is at risk of heart failure without immediate care.

Continue reading “This AI Startup Aims To Predict Heart Failure Before It Happens” »

The first protein-based nano-computing agent that functions as a circuit has been created by Penn State researchers. The milestone puts them one step closer to developing next-generation cell-based therapies to treat diseases like diabetes and cancer.

Traditional synthetic biology approaches for cell-based therapies, such as ones that destroy cancer cells or encourage tissue regeneration after injury, rely on the expression or suppression of proteins that produce a desired action within a cell. This approach can take time (for proteins to be expressed and degrade) and cost cellular energy in the process. A team of Penn State College of Medicine and Huck Institutes of the Life Sciences researchers are taking a different approach.

“We’re engineering proteins that directly produce a desired action,” said Nikolay Dokholyan, G. Thomas Passananti Professor and vice chair for research in the Department of Pharmacology. “Our protein-based devices or nano-computing agents respond directly to stimuli (inputs) and then produce a desired action (outputs).”

Miniaturization is progressing rapidly in many fields, and the trend toward the creation of ever smaller units is also prevalent in the world of robot technology. In the future, minuscule robots used in medical and pharmaceutical applications might be able to transport medication to targeted sites in the body. Statistical physics can contribute to the foundations for the development of such technologies.

A team of researchers at Johannes Gutenberg University Mainz (JGU) has now taken a new approach to the issue by analyzing a group of robots and how they behave as collectives of motile units based on the model of active Brownian particles. The team’s findings demonstrating that there may be an alternative route to realize programmable active matter have been published in Science Advances.

Researchers are looking for new ways to perform tasks on the micro-and nanoscale that are otherwise difficult to realize, particularly as the miniaturization of devices and components is beginning to reach physical limits. One new option being considered is the use of collectives of robotic units in place of a single robot to complete a task.

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links:
At-Home Metabolomics: https://www.iollo.com/?ref=michael-lustgarten.

Continue reading “Blood Test #3 in 2023: Supplements, Diet” »

The ability to acquire gut stem cells via biopsy and have a significant proliferative capacity in culture make them an invaluable resource for autologous cell treatments. In the mouse gut, insulin-producing cells can be produced. Still, human gut tissues have not been able to produce an abundance or durability of insulin-secreting cells to assess their potential as a cell treatment for diabetes.

In a new study, scientists from Weill Cornell Medicine showed that stem cells from human stomach can be converted into insulin-secreting cells. Scientists demonstrated that they could obtain the stem cells from the human stomach and reprogram them directly—with strikingly high efficiency—into cells that closely resemble pancreatic insulin-secreting cells known as beta cells.

In experiments on a mouse model, this approach reversed disease signs. According to scientists, the study offers a promising approach, based on patient’s cells, for type 1 diabetes and severe type 2 diabetes.

The psychedelic substances 5-MeO-DMT causes a long-lasting increase in the number of tiny protrusions called dendritic spines in the brain, according to new research published in Neuropsychopharmacology. The study, which was conducted on mice, sheds light on the behavioral and neural mechanisms of 5-MeO-DMT.

Serotonergic psychedelics (such as psilocybin and LSD) have shown promise as potential therapeutics for mental illnesses like depression and anxiety. Short-acting compounds are particularly interesting because they require less dosing time, which could improve patient access to treatment. In humans, 5-MeO-DMT produces a short-lasting experience due to its rapid breakdown in the body.

“My lab started research on psychiatric drugs like ketamine and psychedelics about 10 years ago. We were motivated by how basic science and clinical research can together powerfully move a drug forward to become medicine. Specifically I believe there is a lot of potential for psychedelics as therapeutics, and that drives our interest in this topic,” said study author Alex Kwan (@kwanalexc), an associate professor in the Meinig School of Biomedical Engineering at Cornell University.

Scientists have enhanced the efficiency of CRISPR/Cas9 gene editing by threefold using interstrand crosslinks, without resorting to viral material for delivery. This approach boosts the cell’s natural repair mechanisms, allowing for more accurate and efficient gene editing, potentially improving disease research and preclinical work.

Gene editing is a powerful method for both research and therapy. Since the advent of the Nobel Prize-winning CRISPR/Cas9 technology, a quick and accurate tool for genome editing discovered in 2012, scientists have been working to explore its capabilities and boost its performance.

Researchers in the University of California, Santa Barbara biologist Chris Richardson’s lab have added to that growing toolbox, with a method that increases the efficiency of CRISPR/Cas9 editing without the use of viral material to deliver the genetic template used to edit the target genetic sequence. According to their new paper published in the journal Nature Biotechnology, their method stimulates homology-directed repair (a step in the gene editing process) by approximately threefold “without increasing mutation frequencies or altering end-joining repair outcomes.”